In this episode, Edward S. Kim, MD, MBA, discusses his path to oncology, how he views disruption in health care, and the ways he’s innovating to help both patients and providers. Intro :13 About Kim :22 The interview 2:03 How did you end up in medicine and oncology? 2:20 What do you think it means to have disruptive or innovative health care strategies? 15:24 Oncology care provides the opportunity for disruptive innovation 21:10 How do you decide which risks to take? 25:59 Taking risks can help move the needle forward 37:52 Kim’s take-away from this episode 38:58 How to reach Kim 39:58 Edward S. Kim, MD, MBA, FACP, FASCO, is physician-in-chief at City of Hope Orange County and vice physician-in-chief of City of Hope National Medical Center. We’d love to hear from you! Send your comments/questions to Dr. Jain at firstname.lastname@example.org. Follow us on Twitter @HemOncToday @ShikhaJainMD. Dr. Kim can be reached by email at email@example.com and on Twitter @DrEdKim. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Kim reports no relevant financial disclosures.
Go online to PeerView.com/GPR860 to view the entire programme with slides. In this activity, an expert in oncology discusses the evolving evidence on molecular testing and treatment of EGFR mutation-positive NSCLC, including new data from real-world studies, and provides practical guidance for nuanced, individualized decision-making related to selection and sequencing of EGFR-targeted therapies throughout the continuum of advanced NSCLC. Upon completion of this activity, participants will be able to: Review the current understanding of the biology of EGFR mutation-based heterogeneity in NSCLC and the clinical roles of EGFR TKIs in the newly diagnosed setting, Assess mechanisms of acquired resistance to EGFR TKIs and their implications for treatment selection in first-line and later lines of therapy in advanced EGFR mutation-positive NSCLC, Discuss real-world evidence on the efficacy and safety of EGFR TKIs and its impact on long-term treatment planning for patients with advanced NSCLC exhibiting EGFR mutations, Employ effective strategies to prevent, mitigate, and manage adverse effects of EGFR TKI therapy to optimize patient outcomes.